Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Rivia launches AI-powered clinical trial data review module, with Scancell as early adopter
(1h)
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
(4h)
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
(5h)
Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
(6h)
Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger
(9h)
BioPharma Dive
Drug price hikes in Germany could push US costs higher, study says
(3h)
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
(5h)
PepGen soars on promising early data for muscular dystrophy drug
(21h)
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
(1d)
London biotech Oyster harvests $60M for tau-targeting brain drugs
(1d)
Endpoints News
Flagship merges two startups; J&J scores a bipolar mania success
(3h)
Beeline reveals Phase 2 lupus data from old Bristol Myers drug
(5h)
UK science minister calls for more life sciences investment
(5h)
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
(6h)
Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko
(7h)
BioSpace
FDA warns Chinese providers of compounding APIs over record-request refusals
(3h)
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
(4h)
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
(4h)
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
(4h)
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
(8h)
STAT News
What MAHA’s support for Russell Brand tells us about the movement
(1h)
BMI alternative would flip obesity diagnosis for millions, study finds
(3h)
Why this former ER doc thinks giving AI less information is sometimes better
(4h)
Senate health committee schedules vote on FDA commissioner nominee Overton
(4h)
We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
(5h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Tzuchman-Katz
(1d)
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(2d)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(1w)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(1w)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Drug Channels
The State of Employer Pharmacy Benefits in 2026: When Plan Savings Come From Higher Patient Costs
(1d)
BlinkRx Insights: Clarifying the Mystery around “DTP”
(5d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(6d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(1w)
Biopharma’s AI Fork in the Road
(1w)
European Biotechnology Magazine
VectorY secures €74.5M to advance ALS gene therapy trial
(5h)
Austria builds life sciences momentum
(5h)
SRTD raises €31.5M seed round to develop cell-selective RNA therapies
(1d)
Swiss VC Redalpine closes eighth fund at $250 million
(1d)
Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain
(1d)
Drug Hunter
DNA-Encoded Libraries Expand the Reach of Hit Discovery
(4h)
GSK3882347
(1d)
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(2d)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(2d)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(5d)
Labiotech.EU
Preclinical Pulse: The research catching our eye in November 2026
(1d)
Zooming out from ovaries: how has renaming PMOS changed lives?
(5d)
How to turn a BIO-Europe meeting into a lasting partnership
(5d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(1w)
The biggest biotech funding rounds in October 2026
(1w)
Bio IT World
Biosecurity Is Too Important to Be Left Unregulated
(13h)
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(1d)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(4d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(6d)
Quantifying the Average Human Genome
(1w)
GEN News
How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years
(1d)
From Farm Waste to Medical Nanoparticles
(1d)
Hybrid Model Captures Lactate Run-Away and Back-Metabolism
(1d)
Extracellular Vesicle Product Developer Creates Potency Assay
(1d)
Automation a Path to Lower Cell Therapy Costs
(1d)
Cure Today
Living With BRCA and Ovarian Cancer: Leanne Citrone's Story
(1h)
Patient Advocacy Advice From a Colon Cancer Survivor
(3h)
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
(5h)
Inside the Clinic: How One Hematologist Approaches a Rare Leukemia
(22h)
The Day I Tapped My Son Out of Basic Training
(23h)
Contract Pharma
Valo Health Merges with Montai Therapeutics, Company Will Keep Valo Name
(11m)
Neuvivo Appoints Mike McGrath as CEO
(15m)
Devia Spins Out of Visium to Aid Pharma Companies with GxP Deviations
(1h)
FDA Approves Merck, Darmstadt, Germany’s Pimjetmi for Symptomatic TGCT
(2h)
T-Cypher Bio Expands Oxford Operations with Move to Abingdon Science Park
(3h)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(2mo)
Medcity News
Follow the Leader: How to Build and Retain Great Clinical Teams
(5h)
Oura’s Buys Counsel for $625M, But Will Payers and Consumers Get on Board?
(19h)
FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke
(22h)
New Campaign Wants AI Applications To Look Beyond Speed
(1d)
The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist
(1d)
Chemical & Engineering News
Sorry, it’s a scam—what to look out for in your job search
(39m)
Periodic Graphics: Fighting flu: How flu vaccines are made
(3h)
C&EN Chempics Close-Ups, Nov. 11
(6h)
California voters OK $8.4 billion for immunology amid funding questions
(21h)
Business Watch: 3M settles PFAS cases for $7.35 billion, and more
(1d)
The Pharma Letter
VectorY raises 74.5 million euros to take TDP-43 ALS therapy through Phase I/II readout
(2h)
Teva targets $6-7 billion innovative medicines revenue by 2030 at first R&D Day
(3h)
Positive new Phase III data for Amgen’s dazodalibep
(4h)
Shionogi enters license agreement with Link for cefiderocol
(5h)
Kesmalea rebrands as Oyster with $60 million, Lilly-backed round for oral tau degrader
(5h)
Targeted Oncology
Dr Garmezy on JNJ-6143's Novel Mechanism in Advanced Prostate Cancer
(35m)
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
(1h)
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
(2h)
Novocure’s Optune Mya Gets FDA Not Approvable Letter
(3h)
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
(4h)
MedWatch
Trump’s drug pricing policy could delay new medicines in Europe
(5h)
Two boards are plenty for Lundbeck CEO: “It’s about becoming a better CEO”
(6h)
Lundbeck CEO plays down margin pressure from Vyepti’s success
(6h)
Moderna CEO sees personalized cancer vaccine as potential best-seller
(9h)
Lilly to seek FDA approval for Foundayo in sleep apnea after strong Phase 3 data
(9h)
In The Pipeline
Think Before You Degrade
(22h)
Jon Clardy, 1943-2026
(2d)
Antimicrobial Peptides for Fun (?) and Profit (?)
(6d)
The Morning After the Midterms
(1w)
Taming Photochemistry
(1w)
Pharmaphorum
Obesity needs a new clinical definition, study finds
(5h)
Google Cloud launches Gemini for Healthcare
(6h)
UK's Levicept builds case for osteoarthritis therapy at ACR
(7h)
AZ boosts vaccine capabilities with Omniose buy
(8h)
Merck's rare tumour drug Pimjetmi claims FDA approval
(9h)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(2w)
Why we need to rethink childhood cancer treatments
(2w)
Q3 UK biotech VC heads for record year thanks to megadeals
(2w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
HIT Consultant
WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans
(7h)
TigerConnect Smart Room Suite: Integrating Epic, Cloud Alarm Management, and Bedside AI
(13h)
Oscar Health and HealthEx Leverage TEFCA Individual Access to Bring Medical Records into AI Workflows on Day One
(14h)
How Real-World Data (RWD) Is the Turning Point for Pharma Innovation
(14h)
M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care
(1d)
Insights: Pink Sheet
Why The EU JCA For AstraZeneca’s Etcamah Took More Than 100 Days
(4h)
Fast Approval, Delayed Start? EU Speeds Modifications To Clear Trial-Blocking Conditions
(4h)
WuXi AppTec Removed From 1260H List, For Now
(13h)
US FDA Reorg Will Help Address ‘Surge’ In Cell, Gene Therapy Facility Inspections
(20h)
Operation TrialBlazer: US FDA’s Expedited IND Pilot Draws 100+ Applications
(20h)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(20h)
GoodRx partners with Google Cloud to bring prescription savings into Gemini for healthcare
(3h)
Veristat, Clene use AI to speed up ALS drug application by 80%
(3h)
Build-a-biotech: Transitioning from academia to commercialization
(7h)
Tighter rules with COINS, DOJ-HHS and EHDS
(22h)
BioCentury
PepGen’s DM1 readout hints at functional payoff from splicing correction
(19h)
SITC 2026: Dual targeting, precise integration shape in vivo CAR T development
(20h)
FDA approvals on track for record year
(21h)
Boehringer in six-program tie-up with Sino: Deals Report
(1d)
Overton confirmation unlikely, Brenner under consideration as acting FDA commissioner
(1d)
SCRIP
Oyster Therapeutics Raises $60m To Target Alzheimer’s With Protein Degraders
(2h)
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
(2h)
Beam Eyes Risto-Cel BLA As Early As Year-End After Positive Sickle Cell Data
(8h)
ACR 2026: Can ImmuneOnco‘s Bispecific Take On Roche’s Gazyva In SLE?
(10h)
Divamics Targeting Differentiation In Application Of AI To Drug Design
(12h)